Conducting clinical trials in outbreak settings: Points to consider

Clinical Trials

Volumn 13, Issue 1, 2016, Pages 92-95

  Clifford Lane, H ^a   Marston, Hilary D ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); EPIDEMIC; HEALTH CARE ACCESS; HUMAN; MEDICAL ETHICS; PARAMETERS; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STANDARD; STUDY DESIGN; STUDY OVERSIGHT; TRANSPARENCY; AFRICA; ETHICS; HEMORRHAGIC FEVER, EBOLA; METHODOLOGY; PROCEDURES;

AFRICA, WESTERN; CLINICAL TRIALS AS TOPIC; DISEASE OUTBREAKS; HEMORRHAGIC FEVER, EBOLA; HUMANS; RESEARCH DESIGN;

EID: 84957569908     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774515618198     Document Type: Review

References (5)

1. Emanuel EJ, Wendler D, Killen J, et al. What makes clinical research in developing countries ethical? The benchmarks of ethical research. J Infect Dis 2004; 189: 930-937.
2. Proschan M, Dodd LE, Price D,. Statistical considerations for a trial of Ebola virus disease therapeutics. Clin Trials 2016; 13: 39-48.
3. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514: 47-53.
4. National Institutes of Health. Starting antiretroviral treatment early improves outcomes for HIV-infected individuals. NIH-funded trial results likely will impact global treatment guidelines, http://www.niaid.nih.gov/news/newsreleases/2015/Pages/START.aspx# (2015,. accessed 1 October 2015).
5. National Institutes of Health. Statement: NIH discontinues immunizations in HIV vaccine study., http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HVTN505April2013.aspx (2013,. accessed 1 October 2015).